Browsed by
Tag: Janus

Janus Henderson and PMV Pharmaceuticals See Activist Action

Janus Henderson and PMV Pharmaceuticals See Activist Action

Text size

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Oct. 1 through Oct. 7, 2020. Source: InsiderScore.com

Activist Holdings


Janus Henderson Group

(JHG)

Trian Fund revealed an initial investment in the investment manager of 18,066,612 shares. That figure includes the purchase of 9,134,262 Janus Henderson shares at prices ranging from $19.10 to $20.57 each from Sept. 22 through Oct. 1. Trian reported that it had discussions with Janus Non-Executive Chairman Richard Gillingwater, and intends to talk to other members of Janus’ board and executive management “regarding various strategic and operational initiatives.”

Trian said that “due to a variety of competitive pressures” within the asset-management industry, those that “possess significant scale and product breadth” as well as have the means for technology innovation will be in the best position to serve clients. To that end, Trian “may encourage [Janus] to explore certain strategic combinations…with one or more companies in the asset-management industry,” in which Trian may be or soon be an investor. Trian also disclosed a new investment in

Invesco

(IVZ) the same day it reported its 9.9% stake in Janus.

Original Filings


PMV Pharmaceuticals

(PMVP)

OrbiMed Advisors reported its first interest in the newly public oncology-based biopharmaceutical firm. OrbiMed bought 950,000 shares through PMV Pharmaceutical’s initial public offering that closed on Sept. 29 and priced shares at $18 each. Combined with the PMV shares that OrbiMed received through the automatic conversion of pre-IPO preferred securities, OrbiMed holds 6,589,330 common shares, equal to 14.7% of PMV’s outstanding stock.


Dyne Therapeutics

(DYN)

Vida Ventures Advisors reported a new investment in the

Read the rest